Related Experiment Videos
Perspectives on anthracyclines plus ifosfamide in advanced soft tissue sarcomas
P Casali1, U Pastorino, A Azzarelli
1Division of Medical Oncology, Istituto Nazionale Tumori, Milan, Italy.
Cancer Chemotherapy and Pharmacology
|January 1, 1993
Summary
Doxorubicin and ifosfamide combination therapy shows higher response rates for adult soft tissue sarcomas but requires careful patient selection due to myelotoxicity. Survival benefits are likely limited to specific patients undergoing combined chemotherapy and surgery.
Area of Science:
- Medical Oncology
- Pharmacology
- Clinical Trials
Background:
- Soft tissue sarcomas (STS) in adults are primarily treated with doxorubicin and ifosfamide.
- Combination chemotherapy with these agents, sometimes including dacarbazine, improves response rates over single-agent therapy.
Purpose of the Study:
- To evaluate the efficacy and safety of combined doxorubicin and ifosfamide in adult soft tissue sarcoma treatment.
- To determine if higher response rates translate to improved survival outcomes.
Main Methods:
- Review of combination chemotherapy regimens (doxorubicin, ifosfamide, +/- dacarbazine) for adult STS.
- Analysis of response rates and survival data in relation to treatment intensity and patient characteristics.
Main Results:
- Full-dose combination chemotherapy demonstrated higher response rates compared to single agents.
- Significant myelotoxicity necessitates reserving full-dose regimens for patients with good performance status and no septic foci.
- Improved survival is not guaranteed solely by higher response rates.
Conclusions:
- Full-dose polychemotherapy for STS may offer survival benefits primarily in selected patients undergoing combined modality treatment (chemotherapy and surgery).
- Further prospective trials are needed to refine treatment strategies and improve cure rates in specific patient subgroups.